Plasmonic Substrates are the basis for High-Sensitivity Fluorescence-Immunoassays
(∗ developed with Blu-Ray Technologie in Cooperation with Sony DADC Biosciences GMBH, now STRATEC Consumables GMBH )
 

 

FIANOSTICS welcomes

Josef Schabauer

Our new Partner


After studying Natural Sciences at the University of Natural Resources and Applied Life Sciences Vienna, Josef started his professional career at Unilever. In 1989, he joined Abbott, a global leader in the healthcare industry. Josef held several leading management positions at Abbott: Commercial Manager Abbott Diagnostics Austria, Customer Experience Director of the DACH- and BeNeLux region, Managing Director of Abbott Diagnostics Switzerland and CEO/County Manager Abbott Austria GesmbH, among others.
In the beginning of 2020, Josef became partner at FIANOSTICS. He will use his significant industry expertise in vitro diagnostics as well as his long-lasting networks to drive our strategic commercialization efforts.

Wiener Neustadt, June 2020
FIANOSTICS is very happy that Josef has joined our team. We are very much looking forward to a successful cooperation. Dr. Gerhard Hawa Founder / CEO
 

 

Our Timeline


2015

Foundation

Formation of Fianostics GmbH

2017

First Product

FluoBolt™-NOGGIN
MEF-FIA for the quantitative determination of NOGGIN in serum and plasma

2018

Second Product

FluoBolt™-ASPORIN
This protein plays an important role in osteoarthritis, lumbar disc damage and tumor progression

2018

ISO 13485:2016


FIANOSTICS obtains certification for ISO 13485:2016 Medical devices - Quality management systems - Requirements for regulatory purposes- As of now our products are available with CE marking

2018

Third Product

FluoBolt™-PERIOSTIN
assay is your high-sensitivity alternative to conventional PERIOSTIN-ELISA kits

2019

Fourth Product


FluoBolt™-KLOTHO
We decided to use our FluoBolt™-Technology to provide a high sensitivity α-KLOTHO assay for clinical research, that may improve data consistency

2020

Fifth Product


FluoBolt™-WNT3A

2020

Further Products


New Biomarkers with high clinical potential to bone metabolism- and neurodegenerative disorders